Department of Neonatology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing Key Laboratory of Pediatrics , Chongqing, China.
Shenzhen Key Laboratory of Synthetic Genomics, Guangdong Provincial Key Laboratory of Synthetic Genomics, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences , Shenzhen, China.
Microbiol Spectr. 2024 Jan 11;12(1):e0188223. doi: 10.1128/spectrum.01882-23. Epub 2023 Nov 28.
Phage therapy is gaining traction as an alternative to antibiotics due to the rise of multi-drug-resistant (MDR) bacteria. This study assessed the pharmacokinetics and safety of PA_LZ7, a phage targeting MDR , in mice. After intravenous administration, the phage showed an exponential decay in plasma and its concentration dropped significantly within 24 h for all dosage groups. Although there was a temporary increase in certain plasma cytokines and spleen weight at higher dosages, no significant toxicity was observed. Therefore, PA_LZ7 shows potential as an effective and safe candidate for future phage therapy against MDR infections.
噬菌体疗法作为抗生素的替代品，由于多药耐药（MDR）细菌的出现而受到关注。本研究评估了针对 MDR 的噬菌体 PA_LZ7 在小鼠体内的药代动力学和安全性。静脉注射后，噬菌体在血浆中呈指数衰减，所有剂量组在 24 小时内浓度显著下降。尽管在较高剂量下某些血浆细胞因子和脾脏重量短暂增加，但未观察到明显的毒性。因此，PA_LZ7 作为一种针对 MDR 感染的有效且安全的噬菌体治疗候选药物具有潜力。
